Keyphrases
Ipilimumab
100%
Nivolumab
94%
Biliary Tract Cancer
84%
Stereotactic Body Radiotherapy
78%
Prognostic Biomarker
63%
Phase II Study
57%
Adjuvant Immunotherapy
52%
Randomized Phase II Trial
52%
Melanoma
52%
Chemotherapy
52%
Confidence Interval
42%
Carbohydrate Antigen 19-9 (CA19-9)
35%
Early Breast Cancer
33%
Pancreatic Cancer
31%
Real Patients
31%
Proximity Extension Assay
31%
Stage III-IV
31%
Interleukin-6
30%
C-reactive Protein
30%
Quality of Life
30%
Health-related Quality of Life
29%
Older Patients
29%
Diagnostic Biomarker
28%
Anti-PD-1
26%
Perceived Benefits
26%
Predictiveness
26%
Bcl-xL
26%
Patients with Breast Cancer
26%
Tocilizumab
26%
Prognostic Value
26%
Needs Assessment
26%
Large B-cell Lymphoma
26%
Locally Advanced Prostate Cancer
26%
Circulating Proteins
26%
Culture Mode
26%
Magnetic Resonance-guided
26%
First-in-man Study
26%
Interleukin-15 (IL-15)
26%
Protein Signature
26%
In Vitro Culture
26%
Blood-based
26%
Singleton Pregnancy
26%
Infradiaphragmatic
26%
Ethylenediaminetetraacetic Acid
26%
Tumor Fibrosis
26%
Dosimetric Parameters
26%
Stereotactic Radiotherapy
26%
Toxicity Evaluation
26%
Metastatic Pancreatic Cancer
26%
Blastocyst
26%
Medicine and Dentistry
Nivolumab
83%
Ipilimumab
78%
Biliary Tract Cancer
78%
Stereotactic Body Radiation Therapy
78%
Pancreas Cancer
52%
Biological Marker
50%
Diagnosis
39%
Interleukin 6
39%
Overall Survival
33%
Immunotherapy
32%
C Reactive Protein
32%
Quality of Life
29%
Neoplasm
28%
Interleukin 15
26%
Stereotactic Radiotherapy
26%
Gastrointestinal Toxicity
26%
Breast Cancer
26%
Fibrosis
26%
Mental Health
26%
Nuclear Magnetic Resonance
26%
Nodular Melanoma
26%
Pancreas Adenocarcinoma
26%
Embryo Culture
26%
In Vitro
26%
Tocilizumab
26%
Radiation Therapy
26%
Dizziness
26%
Cancer Therapy
26%
Advanced Cancer
26%
Adverse Event
23%
Symptom
23%
Extracellular Matrix
21%
Disease
20%
Blastocyst
18%
Embryo Transfer
16%
Progressive Disease
13%
Prevalence
13%
Neuropathy
13%
Proportional Hazards Model
12%
Recurrent Disease
12%
Gastrointestinal Cancer
11%
Multivariate Analysis
11%
Hazard Ratio
10%
Awareness
9%
Collagen Type 4
8%
Lymph Node
8%
Collagen Type 3
8%
Hematological Cancer
8%
Adrenal Gland
8%
Carbon 11
8%
Pharmacology, Toxicology and Pharmaceutical Science
Nivolumab
76%
Biological Marker
73%
Ipilimumab
65%
Immunotherapy
59%
Biliary Tract Cancer
57%
Pancreas Cancer
57%
Melanoma
52%
Malignant Neoplasm
49%
Interleukin 6
39%
Disease
34%
C Reactive Protein
32%
Neoplasm
32%
Overall Survival
29%
Recurrent Disease
29%
Fibrosis
26%
Prostate Cancer
26%
Ethylenediaminetetraacetic Acid
26%
Tocilizumab
26%
Breast Cancer
26%
Interleukin 15
26%
B Cell Lymphoma
26%
Gastrointestinal Toxicity
26%
Vaccination Policy
21%
Comorbidity
17%
Adverse Event
17%
Immunoglobulin
15%
CD8 Antigen
13%
Metastatic Melanoma
12%
Adjuvant
8%
Preclinical Study
8%
Carbon 11
8%
Soft Tissue Metastasis
8%
Metalloproteinase
8%
Immune Checkpoint Inhibitor
8%
Collagen Type 3
8%
Collagen Type 4
8%
Intraperitoneal Injection
8%
Cross Sectional Study
8%
Progression Free Survival
8%
Programmed Cell Death
7%
Gemcitabine
6%
Tumor Microenvironment
6%
Fluorouracil
6%
Recurrence Free Survival
6%
Monotherapy
6%
Mucin
5%
Scatter Factor
5%
Digestive System Cancer
5%
Placental Growth Factor
5%
Plasma Protein
5%